History of human papilloma virus

Anal cancer is cancer that forms in tissues of the anus. The anus is the opening of the rectum last part of the large intestine to the outside of the body. Who can get HPV? Can I prevent HPV? You are more likely to get HPV if you have: sex at an early age, many sex partners, or a sex partner who has had many partners. If there are no signs, why do I need to worry about HPV? What else can I do to lower my chances of getting HPV?

You can choose not to have sex abstinence. If you have sex, you can limit the number of partners you have. Choose a partner who has had no or few sex partners. The fewer partners your partner has had -- the less likely he or she is to have HPV. It is not known how much condoms protect against HPV.

High-risk HPV infections can cause changes in the cells of the cervix and other areas that may lead to cancers. Found early, the affected tissues can be removed via cryosurgery freezing off the lesions or other surgical techniques. If they are not detected and removed, cancer may develop. Surgical intervention at any stage of treatment may lead to complications with pregnancy and childbirth.

Annually latest data from about 12, new cases of cervical cancer occur in U. This figure does not include cases of women who are diagnosed with and treated for HPV-related precancerous conditions. About deaths occur annually in the United States from cervical cancer. About cases of HPV-related anal and throat cancers in women are reported annually. In men, about 12, cases of HPV-related cancers occur per year. A rare complication of HPV involves transmission of the virus from mother to child: during birth, an infant can be exposed to the virus and develop a condition called Recurrent Respiratory Papillomatosis.

The U. A nine-valent vaccine HPV9, Gardasil 9 was approved in The HPV vaccines have been shown to be effective in preventing precancerous cervical changes and precancerous anal changes in women and men caused by high-risk cancer-causing HPV strains.

Current U. The recommended age for HPV vaccination of females is years. The vaccine series can be administered as young as age 9 years. Catch-up vaccination is recommended for females age years who have not been previously vaccinated. The vaccination series can be started beginning at age 9 years. Vaccination with HPV4 or HPV9 is recommended for males age years who have not been vaccinated previously or who have not completed the series.

Males age years may be vaccinated. For all adolescents, the vaccine is given as a 2-dose series if the series is initiated before age If the series is begun at age 15, 3 doses of vaccine are given.

Center for Disease Control and Prevention. Cervical cancer statistics. HPV and men- Fact sheet. March 27, De Kok, I. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer. GAVI Alliance. Human Papillomavirus vaccine support. De Martel C.

Sabeena S. Global human papilloma virus vaccine implementation: An update. Changes in cervical human papillomavirus HPV prevalence at a youth clinic in stockholm, sweden, a decade after the introduction of the HPV vaccine.

Cell Infect. LaMontagne D. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. World Health Organ. Banerjee A. Improving immunisation coverage in rural India: Clustered randomised controlled evaluation of immunisation campaigns with and without incentives. Zhou J. Kirnbauer R. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Mitchell T. No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines. Paz-Zulueta M. Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions.

BMC Cancer. Schellenbacher C. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. Huber B. Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis. Lancet Infect.

Schwarz T. Vaccines Immunother. Lehtinen M. Cancer Discov. Castle P. Prophylactic HPV vaccination: Past, present, and future.

Harper D. HPV vaccines—A review of the first decade. Draper E. Saadeh K. Joura E. Zhai L. Gardasil A global survey of projected efficacy. Buchanan T. Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines.

Guevara A. Roden R. Opportunities and challenges for human papillomavirus vaccination in cancer. Drolet M. Taira A. Evaluating human papillomavirus vaccination programs.

Baussano I. Human papillomavirus vaccination at a time of changing sexual behavior. Human papillomavirus type distribution in 30, invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication.

Clifford G. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Ogembo R. Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: A systematic review and meta-analysis. Hirth J. Gelman A. Racial disparities in human papillomavirus vaccination: Does access matter? Spencer J. Disparities and reverse disparities in HPV vaccination: A systematic review and meta-analysis.

Dixon B. An educational intervention to improve HPV vaccination: A cluster randomized trial. Thompson B. Cancer Causes Control. Cory L. Effects of educational interventions on human papillomavirus vaccine acceptability: A randomized controlled trial.

Larasati L. Brewer N. Announcements versus conversations to improve HPV vaccination coverage: A randomized trial. Dempsey A. Effect of a health care professional communication training intervention on adolescent human papillomavirus vaccination: A cluster randomized clinical trial. JAMA Pediatr. Herrera-Ortiz A.

Public Health. Karlsson R. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: A population-based study. Vaccarella S. Cancer Epidemiol. Biomarkers Prev. Chelimo C. Risk factors for and prevention of human papillomaviruses HPV , genital warts and cervical cancer. Chan J. Sex of sexual partners and human papillomavirus vaccination among U.

Brouwer A. HPV vaccination has not increased sexual activity or accelerated sexual debut in a college-aged cohort of men and women. BMC Public Health. Bogaards J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: Bayesian evidence synthesis. World Health Organization. World Health Organization; Geneva, Switzerland: Comprehensive cervical cancer control: A guide to essential practice. Petrosky E. MMWR Morb. Sonawane K. HPV tests are not recommended to screen men, adolescents, or women under the age of 30 years.

Most people with HPV do not know they have the infection. They never develop symptoms or health problems from it. Some people find out they have HPV when they get genital warts. Women may find out they have HPV when they get an abnormal Pap test result during cervical cancer screening. In that same year, there were 13 million new infections.

Cervical cancer: Every year, nearly 12, women living in the U. More than 4, women die from cervical cancer—even with screening and treatment. There are other conditions and cancers caused by HPV that occur in people living in the United States.

Every year, about 19, women and 12, men experience cancers caused by HPV. This could be less than the actual number of people who get genital warts. Pregnant people with HPV can get genital warts or develop abnormal cell changes on the cervix.

Routine cervical cancer screening can help find abnormal cell changes. You should get routine cervical cancer screening even when you are pregnant. There is no treatment for the virus itself. However, there are treatments for the health problems that HPV can cause:.